Upadacitinib

🧮 Dose calculator

Rheumatoid arthritis · Regimen source: FDA Rinvoq · 2.3

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Rinvoq · 8.1

  “Risk Summary Available data from the pharmacovigilance safety database and postmarketing case reports on use of RINVOQ in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or miscarriage.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Rinvoq · 8.2

  “Because of the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with RINVOQ/RINVOQ LQ, and for 6 days (approximately 10 half-lives) after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Rinvoq · 8.4

  “Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis The safety and effectiveness of RINVOQ/RINVOQ LQ in pediatric patients 2 to less than 18 years of age with pJIA and psoriatic arthritis have been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Rinvoq · 8.5

  “Rheumatoid Arthritis and Psoriatic Arthritis Of the 4381 patients treated in the five clinical trials, a total of 906 rheumatoid arthritis patients were 65 years of age or older, including 146 patients 75 years and older.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Rinvoq · 8.3

  “Contraception Females Based on animal studies, upadacitinib may cause embryo-fetal harm when administered to pregnant women [see Use in Specific Populations ( 8.1 )] .”